RNA mystery solved in triple negative breast cancer

December 02, 2015

(PHILADELPHIA) -- Researchers at Thomas Jefferson University have discovered why conventional efforts to block a tiny strand of ribonucleic acid, called microRNA, in triple negative breast cancer cells failed. In a study published December 2nd in the journal PLOS ONE, the new insight enables effective design of RNA blockers against previously intractable microRNAs.

"Triple negative breast cancer is one of the most aggressive forms of breast cancer, and there's been a lot of excitement in blocking the microRNAs that appear to make this type of cancer grow faster and resist conventional treatment," says senior author Eric Wickstrom, Ph.D., a Professor in the Department of Biochemistry and Molecular Biology at the Sidney Kimmel Medical College at Thomas Jefferson University. "However blocking microRNAs hasn't met with great success and this paper offers one explanation for why that might be the case."

"Triple negative breast cancer strikes younger women, tragically killing them in as little as two years," says first author Yuan-Yuan Jin, Ph.D. candidate in the Department of Biochemistry and Molecular Biology. "Only chemotherapy and radiation are approved therapies for triple negative breast cancer. We want to treat a genetic target that will keep patients alive with a good quality of life."

The researchers targeted a microRNA called miR-17 that is known to spur triple negative breast cancer growth by interfering with genes that would normally signal a diseased or early-cancerous cell to die. Specifically, miR-17 blocks the tumor suppressor genes PDCD4 and PTEN.

However, when Jin tried to diminish miR-17 levels in triple negative cancer cells, rather than increase the levels of the tumor suppressor genes, as they had expected, they saw an even greater decrease in these genes than when the miR-17 was left untouched.

The current dogma in the field states that microRNAs, which are double stranded, only silence genes using one of their two strands. The matching, so-called passenger strand is thought to be discarded and degraded by the cell.

Although there have been some instances of both strands actively suppressing gene targets, researchers commonly use a method to silence microRNAs that involves flooding the cell with modified RNA sequences that mimic the passenger strand and bind to the single-stranded microRNA before it reaches its target.

When Jin used this method to block miR-17, she saw more silencing of the PDCD4 and PTEN genes, not less. Using bioinformatics and folding-energy calculations, the lead author realized that both strands of miR-17 were active in suppressing PDCD4 and PTEN genes in triple negative breast cancer cells. Jade Andrade, then an undergraduate at Haverford College, calculated a structural explanation for the success of the tiny microRNA passenger strands in modulating gene activity.

"Rather than blocking miR-17, we were inadvertently boosting its levels, and therefore boosting the cell's cancerous potential," says Jin. The experimental results open a pathway to design specific blockers of one microRNA strand without imitating the opposite strand. "We are now testing new miR-17 blocker designs made possible by these results," says Dr. Wickstrom, who is also a researcher at the Sidney Kimmel Cancer Center at Thomas Jefferson University.
-end-
The study was supported by NIH grant R01 CA148565. Thomas Jefferson University has filed a patent application for this discovery. Nikita RNA LLC, founded by co-inventors Dr. Wickstrom and Ms. Jin, has licensed that patent application for drug development.

Article Reference: Y Jin, et al., "Non-specific blocking of miR-17-5p guide strand in triple negative breast cancer cells by amplifying passenger strand activity," PLOS ONE, DOI:10.1371/journal.pone.0142574, 2015.

For more information, contact Edyta Zielinska, 215-955-5291, edyta.zielinska@jefferson.edu or Colleen Cordaro, 215-955-2238, colleen.cordaro@jefferson.edu.

About Jefferson -- Health is all we do.

Our newly formed organization, Jefferson, encompasses Thomas Jefferson University and Jefferson Health, representing our academic and clinical entities. Together, the people of Jefferson, 19,000 strong, provide the highest-quality, compassionate clinical care for patients, educate the health professionals of tomorrow, and discover new treatments and therapies that will define the future of health care.

Jefferson Health comprises five hospitals, 13 outpatient and urgent care centers, as well as physician practices and everywhere we deliver care throughout the city and suburbs across Philadelphia, Montgomery and Bucks Counties in Pa., and Camden County in New Jersey. Together, these facilities serve more than 78,000 inpatients, 238,000 emergency patients and 1.7 million outpatient visits annually. Thomas Jefferson University Hospital is the largest freestanding academic medical center in Philadelphia. Abington Hospital is the largest community teaching hospital in Montgomery or Bucks counties. Other hospitals include Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; and Abington-Lansdale Hospital in Hatfield Township.

Thomas Jefferson University enrolls more than 3,900 future physicians, scientists, nurses and healthcare professionals in the Sidney Kimmel Medical College (SKMC), Jefferson Colleges of Biomedical Sciences, Health Professions, Nursing, Pharmacy, Population Health and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center.

For more information and a complete listing of Jefferson services and locations, visit http://www.jefferson.edu.

Thomas Jefferson University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.